PRX and Alzheimer disease: Densitometric analysis, of both shown and not shown immunoblot data (AD, n=6; control, n=5), revealed an approximately 80% increase in the amount of oxidized to non-oxidized Prx in AD compared to control specimens (Fig. 1E).